Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification

Ancker, Willemijn van den; Terwijn, Monique; Westers, Theresia M.; Merle, Pauline A.; Beckhoven, E van; Dräger, A.M.; Ossenkoppele, Gert J.; Loosdrecht, Arjan A. van de

doi:10.1038/leu.2010.119

Cited by 54 publications

(30 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we have found 6.01% cases of MPAL; however, Ancker et al 9 found the prevalence of MPAL to be 5.0%. Out of 11 cases of MPAL, 5 cases (45.45 %) were in paediatric age group (<15 years) and 6 cases (54.55%) were in adult age group is similar to Owaidah TM et al 10 They found 11 patients (47.82%) were aged 14 years or less and the other 12 cases (52.17%) were adults.…”

Section: Typescontrasting

confidence: 79%

Flow Cytometric Immunophenotyping of Acute Leukaemia With Special Reference to Mixed Phenotypic Acute Leukaemia

Khakhlari¹,

Gogoi²,

Barua³

et al. 2017

jemds

View full text Add to dashboard Cite

BACKGROUNDAcute leukaemias are classified according to their characterisation of either the myeloid or lymphoid lineage. Immunophenotyping for various intracellular and extracellular cell lineage specific markers is an important feature in differentiating between acute myeloid leukaemia (AML) and acute lymphoid leukaemia (ALL). In about 5% cases of Acute Leukaemia, it is not clear whether blasts are derived from myeloid or lymphoid progenitors and are classified as Mixed Phenotypic Acute Leukaemia (MPAL). Our study aimed to analyse the prevalence of MPAL.

show abstract

Section: Typescontrasting

confidence: 79%

Flow Cytometric Immunophenotyping of Acute Leukaemia With Special Reference to Mixed Phenotypic Acute Leukaemia

Khakhlari¹,

Gogoi²,

Barua³

et al. 2017

jemds

View full text Add to dashboard Cite

show abstract

“…27 In 517 pediatric and adult Dutch patients with acute leukemia, 30 patients (5.8%) would be considered as having BAL based on EGIL criteria, and 8 cases (1.5%) were consistent with MPAL using the WHO 2008 classification; only 6 patients (1.1%) would qualify as both BAL and MPAL, suggesting that these classification systems may select different patients. 28 …”

Section: Natural History Of Mpal Incidencementioning

confidence: 99%

How I treat mixed-phenotype acute leukemia

Wolach

Stone

2015

Blood

132

139

View full text Add to dashboard Cite

Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe this entity. MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 World Health Organization monograph on classification of tumors of hematopoietic and lymphoid tissues. In adult patients, MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities. No prospective, controlled trials exist to guide therapy. The limited available data suggest that an “acute lymphoblastic leukemia–like” regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended. The role of immunophenotypic and genetic markers in guiding chemotherapy choice and postremission strategy, as well as the utility of targeted therapies in non–Ph-positive MPALs is unknown.

show abstract

“…Коэкспрессия лимфоидных маркеров CD2 и CD7 не является отличительной особенностью [4,7]. У детей лейкозные клетки характеризуются вы-раженной экспрессией антигенов CD33, CD4, CD65 и HLa-DR, слабо экспрессируются CD34, CD13 и CD14.…”

Section: рис 2 проточно-цитометрический анализ клеток лизированногоunclassified

“…Каждая из указанных структурных перестроек хромосом приводит к образованию слитного гена, кодирующего химерный белок. Эти хромосом-ные нарушения ассоциированы со специфическим аберрантным иммунофенотипом лейкозных клеток [3][4][5]. В связи с этим выявление специфического антигенного профиля бластных клеток миелоидно-го или лимфоидного происхождения дает возмож-ность заранее предполагать наличие определенной генетической аномалии, что облегчает задачу для дальнейших генетических исследований и способ-ствует более быстрому установлению диагноза.…”

unclassified

Neoplasm cell’s immunophenotypic profile in cases of the acute leukaemia with recurrent genetic abnormalities

Сухина¹,

Nikitin²,

Kolyubaeva³

et al. 2015

Lab. sluzh.

View full text Add to dashboard Cite

Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification

Cited by 54 publications

References 5 publications

Flow Cytometric Immunophenotyping of Acute Leukaemia With Special Reference to Mixed Phenotypic Acute Leukaemia

Flow Cytometric Immunophenotyping of Acute Leukaemia With Special Reference to Mixed Phenotypic Acute Leukaemia

How I treat mixed-phenotype acute leukemia

Neoplasm cell’s immunophenotypic profile in cases of the acute leukaemia with recurrent genetic abnormalities

Contact Info

Product

Resources

About